CA2274855A1 - Antagonistes de leukotriene contre l'epithelioma spinocellulaire oral - Google Patents

Antagonistes de leukotriene contre l'epithelioma spinocellulaire oral Download PDF

Info

Publication number
CA2274855A1
CA2274855A1 CA002274855A CA2274855A CA2274855A1 CA 2274855 A1 CA2274855 A1 CA 2274855A1 CA 002274855 A CA002274855 A CA 002274855A CA 2274855 A CA2274855 A CA 2274855A CA 2274855 A1 CA2274855 A1 CA 2274855A1
Authority
CA
Canada
Prior art keywords
alkyl
ethyl
solvate
pharmaceutically acceptable
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002274855A
Other languages
English (en)
Inventor
Jerome Herbert Fleisch
William Thomas Jackson
Jason Scott Sawyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2274855A1 publication Critical patent/CA2274855A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés destinés à traiter ou à prévenir l'épithélioma spino-cellulaire oral. Ces procédés impliquent d'administrer une dose efficace d'un composé présentant une activité d'antagoniste de leukotriène B4 à un sujet mammifère qui nécessite un tel traitement.
CA002274855A 1996-12-13 1997-12-02 Antagonistes de leukotriene contre l'epithelioma spinocellulaire oral Abandoned CA2274855A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3426996P 1996-12-13 1996-12-13
US60/034,269 1996-12-13
US4087497P 1997-03-21 1997-03-21
US60/040,874 1997-03-21
PCT/US1997/021953 WO1998025615A1 (fr) 1996-12-13 1997-12-02 Antagonistes de leukotriene contre l'epithelioma spinocellulaire oral

Publications (1)

Publication Number Publication Date
CA2274855A1 true CA2274855A1 (fr) 1998-06-18

Family

ID=26710754

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002274855A Abandoned CA2274855A1 (fr) 1996-12-13 1997-12-02 Antagonistes de leukotriene contre l'epithelioma spinocellulaire oral

Country Status (14)

Country Link
EP (1) EP0964683A4 (fr)
JP (1) JP2001509142A (fr)
KR (1) KR20000069452A (fr)
CN (1) CN1245429A (fr)
AU (1) AU726215B2 (fr)
CA (1) CA2274855A1 (fr)
EA (1) EA002742B1 (fr)
IL (1) IL130304A0 (fr)
NO (1) NO992846D0 (fr)
NZ (1) NZ335922A (fr)
PL (1) PL334241A1 (fr)
TR (1) TR199901307T2 (fr)
UA (1) UA47505C2 (fr)
WO (1) WO1998025615A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001282717A1 (en) 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
US8093253B2 (en) * 2008-03-06 2012-01-10 Hoffmann-La Roche Inc. Leukotriene B4 inhibitors
KR101898879B1 (ko) 2014-03-05 2018-09-14 재단법인 진안홍삼연구소 홍삼 가공 추출물을 유효성분으로 함유하는 구강편평세포암의 예방, 개선 또는 치료를 위한 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6372648A (ja) * 1986-09-16 1988-04-02 Sumitomo Pharmaceut Co Ltd 新規不飽和脂肪酸誘導体
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
EP0544488B1 (fr) * 1991-11-25 1998-03-11 Eli Lilly And Company Antagonistes du leucotriène substitués par phénylphénol

Also Published As

Publication number Publication date
IL130304A0 (en) 2000-06-01
UA47505C2 (uk) 2002-07-15
NO992846L (no) 1999-06-11
EA002742B1 (ru) 2002-08-29
WO1998025615A1 (fr) 1998-06-18
PL334241A1 (en) 2000-02-14
EP0964683A4 (fr) 2002-08-14
NO992846D0 (no) 1999-06-11
AU7845198A (en) 1998-07-03
EP0964683A1 (fr) 1999-12-22
AU726215B2 (en) 2000-11-02
JP2001509142A (ja) 2001-07-10
CN1245429A (zh) 2000-02-23
KR20000069452A (ko) 2000-11-25
EA199900543A1 (ru) 2000-02-28
NZ335922A (en) 2000-12-22
TR199901307T2 (xx) 1999-08-23

Similar Documents

Publication Publication Date Title
US5910505A (en) Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
AU686706B2 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
WO1998009603A2 (fr) Compositions contenant des anti-inflammatoires non steroidiens a enantiomeres r et methodes therapeutiques et prophylactiques employant ces compositions
PL179113B1 (pl) Kompozycja farmaceutyczna do leczenia chorób sercowo-naczyniowychi do hamowania ekspresji VCAM-1 w komórkach ludzkich PL PL PL PL
SI9300514A (en) Immunopotentiatory agent and physiologically acceptable salts thereof
WO2001034137A2 (fr) Combinaisons oncolytiques destinees au traitement du cancer
US5998454A (en) Leukotriene antagonists useful for treating iritis
AU726215B2 (en) Leukotriene antagonists for oral squamous cell carcinoma
US5817684A (en) Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke
US5914340A (en) Leukotriene antagonists useful for treating dermatoses
US6673813B2 (en) Methods for identifying and treating resistant tumors
US5543428A (en) Method for treating resistant tumors
WO1998042336A1 (fr) Antagonistes de leucotriene utilises pour le traitement de la gingivite
WO1998042650A2 (fr) Antagonistes de leucotriene utilises dans le traitement de la mucoviscidose
JP2002532553A (ja) 有害な胃腸副作用を引き起こさない有力な抗炎症剤としてのエーテルリゾリン脂質の使用
WO1998025600A1 (fr) Antagonistes d'un leucotriene utilises pour traiter ou empecher la goutte
WO1998042335A1 (fr) Antagonistes des leucotrienes, utiles dans le traitement de la goutte
JPH024729A (ja) アラキドン酸のリポキシゲナーゼ誘導代謝物の生合成を阻害する化合物
MXPA99005402A (en) Leukotriene antagonists for oral squamous cell carcinoma
CZ202899A3 (cs) Leukotrienoví antagonisté pro karcinom orálních skvamózních buněk
JP7603713B2 (ja) 選択的ｓ１ｒアゴニストを使用するウイルス感染、疾患、又は障害の治療
WO2004084886A1 (fr) Utilisation d'inhibiteurs destines a l'inhibition a long terme d'activites d'echange de na+-k+-atpase et/ou na+/h+ pour la preparation d'un medicament destine au traitement intestinal
HK40099691A (zh) 用於治疗前列腺癌的溴结构域(bet)抑制剂
JPH08165237A (ja) 血液流動性改善剤
JPH07228526A (ja) 抗アレルギー性鼻炎剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued